{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:07:47Z","timestamp":1792843667936,"version":"4.5.0"},"reference-count":43,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":348,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to investigate the changes in histological types and causes of death associated with thyroid carcinoma (TC) before and after the introduction of systemic drug therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The records of 503 deceased patients treated for TC and with death from TC between January 2005 and June 2024 were reviewed in this retrospective cohort study. Multivariate logistic regression was applied to assess whether the number of patients with anaplastic TC (ATC) at diagnosis and the number of local-related deaths changed before and after the introduction of lenvatinib (i.e. 2005\u20132014 vs 2015\u20132024).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 503 patients, 157 (31%) had ATC, 253 (50%) had papillary TC (PTC), 67 (13%) had follicular TC (FTC), 17 (3%) had poorly differentiated TC, and nine (2%) had medullary TC. Respiratory insufficiency was the most common fatal condition, occurring in 192 cases (38%), followed by local-related death in 98 cases (19%) and brain-related conditions in 22 cases (4%). We found no difference in the frequency of patients with ATC at diagnosis (32 vs 30%; P-value = 0.772) and the frequency of local-related deaths (19 vs 20%; P-value = 0.736) between 2005\u20132014 and 2015\u20132024. These findings were supported by multivariate logistic regression models that adjusted for other covariates (adjusted P-value = 0.436 and 0.353, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ATC, including anaplastic transformation from PTC and FTC, still accounts for approximately 40% of thyroid cancer deaths after the introduction of systemic drug therapy. Respiratory insufficiency is the most common immediate cause of death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-24-0368","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T11:48:20Z","timestamp":1741261700000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":6,"title":["Analysis of immediate 503 thyroid carcinoma deaths: trend of single institution in 2005\u20132024"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6640-3529","authenticated-orcid":true,"given":"Haruhiko","family":"Yamazaki","sequence":"first","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Yokohama City University Medical Center 1 , , ,","place":["Yokohama, Kanagawa, Japan"]},{"name":"Department of Surgery, Ito Hospital 2 , ,","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiminori","family":"Sugino","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital 2 , ,","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Social Epidemiology, Graduate School of Medicine and School of Public Health\/Hakubi Center, Kyoto University 3 , ,","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Katoh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ito Hospital 4 , ,","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Matsuzu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital 2 , ,","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital 2 , ,","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuji","family":"Nagahama","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital 2 , ,","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yokohama City University School of Medicine 5 , , ,","place":["Yokohama, Kanagawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ito Hospital 2 , ,","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"2026070712535204100_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2026070712535204100_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026070712535204100_bib3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1089\/thy.2021.0662","article-title":"Thyroid cancer incidence and mortality trends in the United States: 2000\u20132018","volume":"32","author":"Megwalu","year":"2022","journal-title":"Thyroid"},{"key":"2026070712535204100_bib4","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00268-023-06976-9","article-title":"Migration of risk classification between the JAES versus ATA guidelines for papillary thyroid carcinoma","volume":"47","author":"Yamazaki","year":"2023","journal-title":"World J Surg"},{"key":"2026070712535204100_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1530\/EC-20-0374","article-title":"Current status of the prognostic molecular markers in medullary thyroid carcinoma","volume":"9","author":"Oczko-Wojciechowska","year":"2020","journal-title":"Endocr Connect"},{"key":"2026070712535204100_bib6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.eprac.2020.11.008","article-title":"Clinicopathological characteristics and prognosis of poorly differentiated thyroid carcinoma diagnosed according to the turin criteria","volume":"27","author":"Huang","year":"2021","journal-title":"Endocr Pract"},{"key":"2026070712535204100_bib7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/cancers12030552","article-title":"Evaluation of the 8th edition TNM classification for anaplastic thyroid carcinoma","volume":"12","author":"Onoda","year":"2020","journal-title":"Cancers"},{"key":"2026070712535204100_bib8","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jcem.84.11.6115","article-title":"Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases","volume":"84","author":"Kitamura","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712535204100_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"2026070712535204100_bib10","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070712535204100_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026070712535204100_bib12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1089\/thy.2016.0072","article-title":"The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study","volume":"26","author":"Onoda","year":"2016","journal-title":"Thyroid"},{"key":"2026070712535204100_bib13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070712535204100_bib14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026070712535204100_bib15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.34657","article-title":"Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study","volume":"129","author":"Oh","year":"2023","journal-title":"Cancer"},{"key":"2026070712535204100_bib16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070712535204100_bib17","first-page":"467","article-title":"A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan","volume":"34","author":"Tahara","year":"2024","journal-title":"Thyroid"},{"key":"2026070712535204100_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2020.12.032","article-title":"Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer","volume":"147","author":"Tahara","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026070712535204100_bib19","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070712535204100_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2022.06.044","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)","volume":"173","author":"Higashiyama","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026070712535204100_bib21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00228-020-02842-y","article-title":"Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study","volume":"76","author":"Yamazaki","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2026070712535204100_bib22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3892\/ol.2023.14002","article-title":"Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer","volume":"26","author":"Iwasaki","year":"2023","journal-title":"Oncol Lett"},{"key":"2026070712535204100_bib23","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1002\/cam4.5219","article-title":"Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma","volume":"12","author":"Yamazaki","year":"2023","journal-title":"Cancer Med"},{"key":"2026070712535204100_bib24","volume-title":"General Rules for the Description of Thyroid Cancer (9th)","author":"Japan Association of Endocrine Surgery and The Japanese Society of Thyroid Pathology","year":"2023"},{"key":"2026070712535204100_bib25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/thy.2017.0102","article-title":"Updated American Joint Committee on Cancer\/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why?","volume":"27","author":"Tuttle","year":"2017","journal-title":"Thyroid"},{"key":"2026070712535204100_bib26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2026070712535204100_bib27","first-page":"128","article-title":"Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN)","volume":"4","author":"Cao","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"2026070712535204100_bib28","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/ijc.31884","article-title":"Thyroid cancer \u201cepidemic\u201d also occurs in low- and middle-income countries","volume":"144","author":"Lortet-Tieulent","year":"2019","journal-title":"Int J Cancer"},{"key":"2026070712535204100_bib29","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S2213-8587(20)30115-7","article-title":"Global trends in thyroid cancer incidence and the impact of overdiagnosis","volume":"8","author":"Li","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070712535204100_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2213-8587(21)00027-9","article-title":"Thyroid cancer incidence trends by histology in 25 countries: a population-based study","volume":"9","author":"Miranda-Filho","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070712535204100_bib31","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1002\/cjp2.356","article-title":"Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma","volume":"10","author":"Gu","year":"2024","journal-title":"J Pathol Clin Res"},{"key":"2026070712535204100_bib32","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2012.42.4457","article-title":"Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer","volume":"31","author":"Yang","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026070712535204100_bib33","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1089\/thy.2020.0929","article-title":"Competing causes of death in older adults with thyroid cancer","volume":"31","author":"Papaleontiou","year":"2021","journal-title":"Thyroid"},{"key":"2026070712535204100_bib34","article-title":"Cause of death among patients with thyroid cancer: a population-based study","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"2026070712535204100_bib35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/thy.2023.0449","article-title":"All-cause and cause-specific mortality among low-risk differentiated thyroid cancer survivors in the United States","volume":"34","author":"Tran","year":"2024","journal-title":"Thyroid"},{"key":"2026070712535204100_bib36","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/00005537-200106000-00011","article-title":"Cause of death in patients with well-differentiated thyroid carcinoma","volume":"111","author":"Beasley","year":"2001","journal-title":"Laryngoscope"},{"key":"2026070712535204100_bib37","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3390\/cancers12082323","article-title":"Clinical course from diagnosis to death in patients with well-differentiated thyroid cancer","volume":"12","author":"Park","year":"2020","journal-title":"Cancers"},{"key":"2026070712535204100_bib38","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019","volume":"6","author":"Maniakas","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026070712535204100_bib39","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1007\/s12325-021-01940-2","article-title":"Outcome of patients with locally advanced metastatic medullary thyroid cancer and induction therapy with tyrosine kinase inhibitors in Slovenia","volume":"38","author":"Grasic Kuhar","year":"2021","journal-title":"Adv Ther"},{"key":"2026070712535204100_bib40","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1089\/thy.2024.0090","article-title":"Neoadjuvant treatment of locally advanced thyroid cancer: a preliminary Latin American experience","volume":"34","author":"Pitoia","year":"2024","journal-title":"Thyroid"},{"key":"2026070712535204100_bib41","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/hed.27735","article-title":"Neoadjuvant therapy to improve resectability of advanced thyroid cancer: a real-world experience","volume":"46","author":"Russell","year":"2024","journal-title":"Head Neck"},{"key":"2026070712535204100_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.surg.2024.08.046","article-title":"Neoadjuvant systemic therapy for inoperable differentiated thyroid cancers: impact on tumor resectability","volume":"177","author":"Dickerson","year":"2025","journal-title":"Surgery"},{"key":"2026070712535204100_bib43","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hed.27025","article-title":"American head and neck society endocrine surgery section and international thyroid oncology group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment","volume":"44","author":"Shonka","year":"2022","journal-title":"Head Neck"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/2\/ETJ-24-0368.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/2\/ETJ-24-0368.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-24-0368\/36891\/etj-24-0368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-24-0368\/36891\/etj-24-0368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:22:09Z","timestamp":1783444929000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/2\/e240368\/4420\/Analysis-of-immediate-503-thyroid-carcinoma-deaths"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-24-0368","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"article-number":"e240368"}}